<DOC>
	<DOCNO>NCT02048059</DOCNO>
	<brief_summary>This Phase 2 study see investigational drug , ANG1005 , shrink tumor cell breast cancer patient recurrent brain metastasis .</brief_summary>
	<brief_title>ANG1005 Breast Cancer Patients With Recurrent Brain Metastases</brief_title>
	<detailed_description>See .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . ≥ 18 year old 2 . Breast cancer 3 . Recurrent brain metastasis breast cancer 4 . At least one radiologicallyconfirmed measurable metastatic brain lesion ( ≥ 0.5 cm ) 5 . Neurologically stable 6 . Karnofsky Performance Status ( KPS ) score ≥ 70 1 . Prior treatment ANG1005/GRN1005 2 . Pregnancy lactation 3 . Inadequate bone marrow reserve 4 . Any evidence severe uncontrolled disease 5 . Patients presence infection include abscess fistula , know infection hepatitis B C HIV 6 . CNS disease require immediate neurosurgery intervention ( e.g. , resection , shunt placement , etc . ) 7 . Known allergy paclitaxel component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ANG1005</keyword>
	<keyword>GRN1005</keyword>
	<keyword>LRP-1</keyword>
	<keyword>Targeted therapy</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Brain metastasis</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Blood-brain barrier</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Breast cancer brain metastasis</keyword>
	<keyword>Triple Negative</keyword>
	<keyword>TNBC</keyword>
	<keyword>HER2-positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Metastatic brain tumor</keyword>
</DOC>